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PART A: LITERATURE REVIEW 
Objectives of literature review 
o To gain an understanding of the prevalence of atrial fibrillation in patients with ischaemic stroke 
in high-, as well as low- and middle-income countries.  
o To understand the aetiology of ischaemic stroke and atrial fibrillation. 
o To evaluate the prevalence of atrial fibrillation in the general population. 
o To understand and compare the morbidity and mortality of cerebrovascular accidents with and 
without atrial fibrillation 
o To assess current screening practices for atrial fibrillation and to understand the challenges 
experienced 
o To briefly explore the burden of disease that cerebrovascular accidents have on the South 
African population  
o To gain insight into the costs incurred on the health system by cerebrovascular accidents.  
Literature search strategy, including inclusion, exclusion and quality criteria 
The literature search strategy consisted of a using a variety of online medical and scientific databases 
including PubMed, NBCI, Google Scholar, and EMBASE, to maximize yield of relevant references to 
this study.  Searches were conducted using MeSH terms, which included “stroke”,” cerebrovascular 
accident”, “Atrial fibrillation”, “ECG”, “cardiac arrhythmia” “cardiovascular disease”,” prevention”, 
“low-income”, “high-income”, “burden of disease”, “epidemiology” “prevalence”, “South Africa”,” 
Sub-Saharan Africa”, “Africa”, “anticoagulation”, “disability adjusted life years”. Searches included 
various combinations of terms and words mentioned above. Abstracts and titles of studies that were 
identified from the search results were reviewed individually. Full text articles were obtained for those 
that were considered relevant.  
The inclusion criteria used were applicable studies published in English in peer reviewed journals and 
not older than 25 years. Full text articles that could not be obtained via the university library portals, or 
that required paid subscriptions, or needed to be purchased, were excluded. Only the English abstracts 
and papers were reviewed, other language-journals were excluded. Further studies for possible 
inclusion were identified by searching through the references of the studies already identified as relevant 
for inclusion in a snowballing fashion.    
The MMed literature review does not require a formal assessment of the quality of papers and this was 
therefore not done. Articles were however screened for applicability and whether or not the results were 
internally and/or externally valid.  
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Summary of literature 
Introduction 
Cerebrovascular disease remains one of the leading causes of morbidity and mortality globally. It affects 
15 million people annually and is responsible for 5 million deaths per annum, contributing to the 
growing burden of non-communicable diseases (NCDs) worldwide. (1,2) Stroke, also known as 
cerebrovascular accident (CVA), is defined as a neurologic deficit caused by a cerebrovascular problem 
which persists for more than 24 hours or causes death within 24 hours. (3) It is characterised by focal 
or global cerebral functional impairment, affecting both motor and sensory function, and rapidly 
evolving. An estimated 80% of strokes globally are ischaemic in nature, and the rest non-ischaemic, 
either being haemorrhagic or secondary to a different cause. International data states that one fourth of 
all ischaemic strokes are cardio-embolic in nature. (3,4) Atrial fibrillation (AF) is the most common 
cardiac arrhythmia worldwide. Embolization of a mural thrombus in a patient with AF is the most 
common mechanism of cardio-embolic stroke, and patients with AF have a fivefold increased risk for 
developing a stroke. (4–6) There is a paucity of data available reporting the prevalence of AF in the 
urban population in South Africa, particularly in patients with CVAs. This aim of this literature review 
was to establish the gain an understanding of the prevalence of atrial fibrillation in patients with an 
ischaemic stroke and to explore challenges with regards to the screening, diagnosis and management 
thereof.   
Aetiology 
An estimated 80% of strokes globally are ischaemic in nature, and the rest non-ischaemic, either being 
haemorrhagic or secondary to a different cause. (4) The list is extensive and not limited to the following 
but the commonly seen causes include cervicocephalic arterial dissection; cavernous and sagittal sinus 
thrombosis; Hypercoagulable state due to deficiencies of protein S, protein C, or antithrombin and 
factor V Leiden mutation;  antiphospholipid syndrome; sickle cell disease; myeloproliferative disorders 
(e.g., leukaemia, lymphoma); Vasculitis; neurosarcoidosis; neurocysticercosis; bacterial and 
tuberculous meningitis, as well as other infectious disease, which often occurs in immunodeficient 
patients predominantly HIV positive patients with opportunistic infections such toxoplasmosis or 
cryptococcal disease. (4,7,8) 
Maredza et al., estimates that in the South African setting, 71% are ischaemic, 21% haemorrhagic and 
the remainder secondary to a different cause, including vasculitis, HIV associated opportunistic 
infections, space-occupying lesions and trauma (9,10) International data states that 25% of all ischaemic 
strokes are cardio-embolic in nature. (3,4) Embolization of a mural thrombus in a patient with AF is the 
most common mechanism, and patients with AF have a fivefold increased risk for developing a stroke 
(4–6) as well as a twofold increased risk of silent cerebral infarction. (5) The presence of AF in patients 
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with newly diagnosed strokes is associated with prolonged hospitalisation, increased persistent 
disability, greater severity of disease, and elevated healthcare costs. (3,11,12) In addition to this, strokes 
that occur in the setting of AF have an increased risk of mortality compared to strokes of other 
aetiologies. (5) 
Prevalence 
Atrial fibrillation is an abnormal cardiac rhythm characterized by rapid and irregular beating 
of the atria, (7) and is defined as one or more episodes of at least 30 seconds of atrial arrhythmia with 
no distinct P-waves. (13) AF is the most common cardiac arrhythmia worldwide, has an estimated 
prevalence of 0,5-3% in the general population within western countries (6,13,14), with a higher 
prevalence in males as compared to females. (5,14). Standard AF risk factors include an older age, male 
sex, smoking, obesity, hypertension, diabetes, myocardial infarction, heart failure, valvular heart 
disease, and cardiac surgery. (4,5) AF can lead to thrombus development within the atria, particularly 
the left atrial appendage, which can cause thromboembolic events. (15) 
AF can be classified as: paroxysmal or intermittent AF, which involves intermittent episodes that 
resolve spontaneously within a week; persistent AF, which is continuous sustained for more than one 
week, which can be reversed through surgical or pharmacological intervention, and permanent AF, in 
which the arrhythmia is constant but not reversible (16), and in which the patient and clinician make a 
joint decision to stop further attempts to restore and/or maintain sinus rhythm. (16,17). Other types of 
AF not mentioned frequently in the literature includes long-standing persistent AF, which is AF that is 
continuous for more than 12 months; non-valvular AF; and “lone” AF. (4,7,17)  Atrial flutter is 
classified as a regular supraventricular tachycardia which is also due to a re-entry circuit within the atria 
and is also associated with an increased risk of stroke. (4,7,16) 
Current data, albeit sparse, indicates that the prevalence of AF in developing countries is slightly lower 
than that of the developed world. (14) Despite this lower prevalence of AF in developing countries,  the 
number of AF related deaths increased 196% from 1990 to 2013 in Sub-Saharan Africa (SSA) (18), as 
did the number of deaths from strokes, particularly ischaemic strokes with a 102% increase. (18) As 
AF becomes more prevalent with age, the incidence of AF is estimated to increase progressively in the 
future with the increased mortality and morbidity associated with it. (14) Interestingly, an observational 
study done by Prefasi et al looked at the prevalence of atrial fibrillation in young patients ( less than 50 
years of age ) suffering from ischaemic stroke, which showed that AF is more common than expected 
in patients with young stroke with increased National Institutes of Health Stroke Scale (NIHSS) scores. 
(19) 
In the United States, AF accounts for approximately 15% of all strokes, 36% of strokes for individuals 
aged >80, and up to 20% of cryptogenic strokes. (12) This means that AF accounts for 100 000-125 
000 embolic strokes per year, of which more than 20% are fatal. (12) A study conducted in Greenland 
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by Bjorn-Mortensen et al showed that more than 30% of patients diagnosed with ischaemic stroke had 
AF and only 5 % were diagnosed prior to stroke – this article suggests that unknown AF is a substantial 
risk factor for stroke (20).  In a Swedish cross-sectional study over a 5 year period, a combination of 
data from Riks-Stroke Swedish Registry and from the Patient Register showed that 33.4% patients with 
ischemic stroke had existing, or newly diagnosed AF. (21) Data on the general prevalence and incidence 
of AF in Africa is sparse, particularly in South Africa with small studies estimating it to be 5.6 cases 
per 100 000 per year (22), with no data available about the prevalence of AF in patients with ischaemic 
strokes in an urban environment. In 2008, Bertram et al., estimated that there are 75 000 strokes in 
South Africa each year, with 25 000 of these fatal within the first month. (23)  
Morbidity and Mortality 
Cerebrovascular disease remains one of the top causes of morbidity and mortality worldwide, both in 
high-income countries (HICs) and low- and middle-income countries (LMICs). (4) In South Africa 
cerebrovascular disease was the fourth leading cause of death in 2016, responsible for 5.1% of deaths 
(24) , and the leading cause of death in individuals 65 years and older. (24) Globally approximately 3% 
of total health care system resources are dedicated to stroke, indicating that cerebrovascular accidents 
contribute to a significant economic burden on countries. (9,25) Stroke severity and in-hospital 
mortality are also significantly greater in those with AF. (16,26,27) AF occurs most commonly in older 
populations, therefore, the increased life expectancy in both developed and developing countries means 
that AF-related stroke has become a growing global public health concern. (16) The associated costs of 
treating the consequences of AF potentially place a significant economic burden on health systems and 
society. (16) A systemic review done by Andrew et al suggested that stroke prevention is difficult 
mainly due to the large percentage of cases of undiagnosed AF in society and poor compliance to 
medication for those with diagnosed AF. (16)  
Diagnostics and screening 
Many patients with AF experience no symptoms; between 24% and 50% of cases are reported as 
undiagnosed. (16,28) Asymptomatic AF is also more common in those with permanent AF than in those 
with paroxysmal AF. (4,12,16) Consequently, AF is often not diagnosed until patients present to 
hospital with a stroke, or it is incidentally diagnosed during routine electrocardiogram (ECG) 
examinations. (16) Alarmingly up to 25 % of patients with AF-related stroke only have this arrhythmia 
diagnosed at the time of the stroke. (28) 
This is concerning since asymptomatic AF affords the same stroke risk as symptomatic AF, and if left 
undiagnosed, may provide additional risks associated with the lack of access to preventive treatments. 
(16) Although the risk of stroke related to AF can be reduced by 64–70% by oral anticoagulation, 
underutilisation of this effective treatment and delayed diagnosis remain major obstacles. (13,28) 
 12 
A trial done by Strahenberg et al in Germany aimed to review the diagnosis of paroxysmal AF by early 
and prolonged continuous Holter monitoring in patients with cerebral ischaemia presenting in sinus 
rhythm. The study showed that prolongation of Holter monitoring in patients with cerebral ischaemic 
events increased the rate of detection of paroxysmal AF up to day 7 which would lead to a relevant 
change in therapy in a substantial number of patients. (13) The study recommended that prolonged 
Holter monitoring should be considered for all patients with unexplained cerebral ischaemia. (13) This 
is echoed in another two studies, the first by Andrew et al where it is stated that the diagnosis of 
intermittent AF may also be complicated by the fact that it may not be identified by a single ECG 
reading. Continuous ECG monitoring for periods of 24 hours or more in stroke patients can 
approximately double the number of AF cases diagnosed when compared to a single short ECG reading.  
(16,29) The second article, echoing the same sentiment by Go et al, the KP-RHYTHM Study, which 
concludes that a greater burden of AF (i.e. the amount of time spent in atrial fibrillation) identified using 
a non-invasive, 14-day continuous electrocardiography monitoring strategy is associated with a higher 
risk of ischaemic stroke and arterial thromboembolism in adults with paroxysmal AF that is independent 
of known stroke risk factors. (15) 
This diagnostic modality may be the gold standard but for many parts of South Africa prolonged Holter 
monitoring for all patients with cerebral ischaemia would be difficult to achieve. Nevertheless 
characterizing the burden of AF in patients with paroxysmal AF could assist patients and physicians in 
having a more informed, shared decision-making discussion about stroke prevention strategies. (15) 
A review done by Yang et al showed that single timepoint pulse palpation, when patients present for 
routine visits, together with confirmatory ECG in elderly adults is potentially feasible and beneficial 
for primary stroke prevention. additional screening with twice-daily intermittent ECGs for 2 weeks may 
be warranted in patients older than 75 years. (30) 
In a Canadian study by Tarride et al, screening for AF in seniors greater than 65 years of age  during 
routine appointments with family physicians was a cost-effective strategy compared with no screening, 
and that single lead-ECG is a highly cost effective strategy with an incremental cost per quality-adjusted 
life-year (QALY) gained of CAD$4788. (31) Current European Society of Cardiology guidelines 
recommend opportunistic screening for AF by pulse taking or ECG rhythm strip instead of a systematic 
approach in people more than 65 years of age. (28,32) AF satisfies most of the World Health 
Organization (WHO) criteria for a disease suitable for screening. (28) Despite this and the studies 
mentioned above the U.S. Preventive Services Task Force (USPSTF), backed by the American Heart 
Association (AHA), in recent months stated that there is not enough evidence to support ECG screening 
for AF in asymptomatic adults ages 65 and older. (33) 
Nonetheless, newer inexpensive technologies, including handheld devices, are promising tools for 
screening. (30)  Tools such as smart phone-based devices have made AF screening in the community 
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more feasible. However the sensitivities and positive predictive values of the current versions of these 
automated diagnostic algorithms for AF have to be further interrogated to increase the cost efficiency 
of such screening programmes. (28) Karmen et al performed a study on the clinical value of using an 
Apple Watch to monitor heart rate and the study concluded that wearable devices may be helpful in 
cardiac monitoring and detecting AF but more studies are needed on this topic. (34) 
Ander et al published a recent study where they demonstrated that patients with cryptogenic stokes who 
have moderate to severe left atrial enlargement (LAE) on transoesophageal echocardiography were 
more likely to have AF than non-AF, and that the  likelihood increases with age and severity of LAE, 
and that anticoagulation should be considered in cryptogenic stroke patients with severe LAE , 
especially those patients who require insertable cardiac monitors. (35) 
Treatment 
A study done in South Africa aimed to review the treatment modalities of AF on a broad scale. Most 
reputable studies focus on treatment modalities in the developed world. Jardine et al attempted to merge 
this gap and assess the treatment modalities of AF in the South African population. The study showed 
that the most prevalent clinical characteristic was hypertension. (65.9%) Rhythm control was used in 
36.1% of patients with class IC and class III antiarrhythmic agents, mainly Amiodarone, while rate 
control, mainly with beta-blockers, was used in the remainder of the patients. Concomitant use of other 
cardiovascular drugs was high, and 75.2% of patients were on warfarin for stroke prevention. 
Therapeutic success, as defined by either the presence of sinus rhythm or rate-controlled AF, was 
achieved in 86.8% of patients as judged clinically by the treating physician, but in only 70.2% according 
to the ECG criterion of a heart rate less than or equal to 80 beats per minute (bpm) at rest, using the 
‘lenient’ rate control criterion of ≤110 bpm proposed by the RACE II trial 90.6% of patients would 
have fulfilled this definition. (36) Anticoagulation plays a major role in the treatment of AF worldwide. 
(13,37,38) Medicare registries and clinical trials have demonstrated the protective effect of Vitamin K 
antagonists such as warfarin on reducing stroke events. (13,37) Furthermore, subtherapeutic 
anticoagulation results in 5-times the odds of an ischemic stroke. (37,39)  
Risk stratification is particularly useful in deciding when to initiate treatment in patients with Non-
Valvular AF. Several scoring systems have been developed to better manage patients with Non-
Valvular AF. The two most popular stratification tools are the CHA2DS2-VASc and CHADS2 scores, 
CHA2DS2-VASc being the updated scoring system of the original CHADS2 score. (3,21,37) These 
tools incorporate the major risk factors for ischaemic stroke and give an unadjusted ischaemic stroke 
rate as a percentage per year. The components include congestive heart failure, hypertension, age equal 
to or greater than 75, diabetes, prior stroke or transient ischaemic attack, vascular disease, and female 
sex. (37) Generally speaking a score of ≥2 is high risk for thromboembolism and is a strong indication 
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for anticoagulation therapy. Patients who qualify for and are initiated on oral anticoagulation have an 
increased risk of bleeding (3,37,39,40). To obtain a bleeding risk the HAS-BLED scoring system was 
developed. The HAS-BLED score is a simple scoring tool that is used to determine a patient’s annual 
bleeding risk. Oral anticoagulation bleeding risk outweighs the benefits of treatment if the HAS-BLED 
score exceeds the CHADS2 score in patients with a CHADS2 score of >2. (37) The components of the 
HAS-BLED score are hypertension, abnormal renal or liver function, stroke, bleeding history, labile 
International normalised ratio (INR), elderly and drug or alcohol abuse. (37) 
A fairly recent South African study by Ntlokotsi et al essentially looked at patients with valve 
replacements, with or without AF, over a three-year period with the optimum INR target ranges for all 
participants estimated to be 2.0– 3.5. (37,41) This study focused on South African black patients, but 
from the relevant data and references in the study the authors conclude that optimum Caucasian-based 
INR are the same for black patients. Alarming though the quality of warfarin anticoagulation of the 
participants with valve replacement was found to be inadequate as indicated by percentage time in 
treatment range (TTR) which was 49.7% for all study participants compared with the ideal TTR of 70% 
and above. (41) With similar results demonstrated by Sonuga et al, looking at anticoagulation outcomes 
of patients on warfarin therapy in an urban hospital in Cape Town, South Africa. (42) Patients with 
low-percentage TTR (a reflection of large variation in INR over time) are at a higher risk of warfarin-
related major bleeding, including haemorrhagic stroke and gastrointestinal bleeding, and 
thromboembolic events. (40) Possible explanations for warfarin’s TTR in this study include non-
compliance, drug-drug interaction, drug- food interactions and patient comorbidities. (37,43) 
Multiple alternatives to warfarin, have been successfully developed for AF stroke prevention. These are 
more commonly known as novel- or direct-acting oral anticoagulants (NOACs and DOACs), and 
include Factor IIa antagonist dabigatran, and Factor Xa antagonist rivaroxaban and apixaban. (44) The 
ROCKET-AF, ARISTOTLE and RE-LY studies have found the DOACs to be non-inferior to warfarin, 
and in some cases superior. (37,45–47) Dabigatran was associated with less stroke rates in non-valvular 
AF compared to patients on dose-adjusted warfarin, with a significantly decreased risk of life-
threatening intracranial bleeds compared with warfarin. (37,47) Rivaroxaban showed similar results, 
with a significant reduction in fatal bleeds in comparison with warfarin (37,45), and similarly Apixaban 
was found to be more effective than warfarin in preventing stroke and systemic embolism with lower 
rates of bleeding. (37,46) The DOACs require less monitoring and have fewer drug interactions than 
the warfarin, but they do have distinct disadvantages. (3,37) A huge limiting factor, particularly in 
LMIC is the cost associated with the DOACs and Warfarin was found to be significantly more cost-
effective than the DOACs, even when a wide range of warfarin-related expenses was included. (39)  
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Lastly the CAABL-AF (California Study of Ablation for Atrial Fibrillation) demonstrated that in this 
large population-based study of hospitalized patients with a diagnosis of nonvalvular AF undergoing 
ablation, the risk of adverse outcomes after ablation was associated with lower mortality, and lower 
ischaemic stroke and haemorrhagic strokes than that observed in nonablated patients. (48) 
Costs 
Globally, approximately 3% of total health care system resources are dedicated to stroke indicating that 
cerebrovascular accidents composes a significant economic burden on countries. (9,25) There is a 
paucity of local data that describes the financial impact of stroke care. The burden of disease due to 
stroke in 2008 in South Africa was 564 000 Disability adjusted life years (DALYs). Of this, 17% is 
contributed by Years lived with disability (YLD). (23) In Maredza et al., it is stated that the ‘total direct 
costs of strokes were estimated to be 2.5-4.2 million in the year 2012 in a small rural community in 
South Africa’. (9). This analysis is based on a population of approximately 90 000 people residing in 
the Agincourt sub-district of Mpumalanga province, north-east of South Africa. (9) In contrast, a study 
done in the United States in 2008 showed that the total direct and indirect costs of stroke was estimated 
to cost the economy an estimated 65.5 Billion dollars, where the indirect costs incurred were due to loss 
of productivity resulting from morbidity and mortality. Although the patient profile and demographics 
of the United States are vastly different to South Africa,  these studies highlight the significant disease 
burden that CVAs pose on the economy of countries. (25) In addition to this, informal stroke care,  
which is carried out by caregivers, often being relatives and comprising of community-based activities; 
domestic activities; and personal activities of daily living,  are often overlooked, but remains of utmost 
importance to maintain stroke survivors in the community resulting in an additional economic and 
social burden. (25,49) 
Conclusion 
Atrial fibrillation is a major risk factor for developing ischaemic cerebrovascular accidents, as well as 
other cardio-embolic complications, particularly in our urban environments. To the researches 
knowledge there is a paucity of data available reporting on the prevalence of AF in the urban population, 
particularly in patients with CVAs. With the increasing population life expectancy, and other 
cardiovascular disease, such as hypertension, diabetes, congestive cardiac failure and valvular heart 
disease the prevalence of AF and its complications will surely increase. Although the risk of stroke 
related to AF can be reduced significantly by oral anticoagulation, underutilisation of this effective 
treatment and delayed diagnosis remain major obstacles. Routine screening practices to detect 
asymptomatic AF in LMIC’s is lacking. and up to 25 % of patients with AF-related stroke only have 
this arrhythmia diagnosed at the time of the stroke. Atrial fibrillation is a modifiable risk factor but 
challenges with regards to screening, diagnosis and management hampers effective control.  
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Identification of gaps in the literature, or needs for further research 
• There is a paucity of data that assesses the prevalence of atrial fibrillation in patients with 
stroke, especially in LMIC’s. 
• Challenges and barriers to perform effective primary screening for AF (in asymptomatic 
patients) should be explored.  
• Challenges and barriers to perform effective secondary screening for AF (in patients with an 
ischaemic stroke) should also be explored. 
• Barriers and challenges to effective and safe anticoagulation practices should be explored.  
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Cerebrovascular disease remains one of the leading causes of morbidity and mortality globally. In South 
Africa, cerebrovascular disease was the fourth leading cause of death in 2016, responsible for 5.1 % of 
all deaths - the leading cause of death in individuals 65 years and older. Atrial fibrillation accounts for 
15% of all strokes and a 25% of patients with AF-related stroke have this arrhythmia diagnosed at the 
time of the stroke. 
Objectives 
This study sets out to determine the prevalence of atrial fibrillation in patients with ischaemic stroke, 
as confirmed on CT scan, at a district level hospital in the Western Cape, South Africa. 
Methods 
This descriptive study was conducted at Mitchell’s Plain Hospital in Cape Town and data was collected 
over a year. Patients diagnosed with a stroke were identified from an electronic patient register and 
relevant radiology and clinical data was sourced retrospectively. The diagnosis of ischaemic stroke was 
confirmed by a CT scan report and ECGs were independently screened by two Emergency Physicians. 
Categorical data was described in percentages and descriptive statistics. Continuous variables were 
described by median and interquartile range (IQR). Statistical significance is defined as a p<0.05. 
Categorical data was compared using the Fisher’s exact test. This project has been approved by UCT 
Human Research Ethics Committee [790/2018]. 
Results  
The proportion of adult patients with a diagnosis of stroke was 2%. Of those, 64% had ischaemic 
strokes, 9% had intracranial bleeds, 20% did not have a CT scan and 7% had stroke mimics. 11% of all 
participants with ischaemic stroke had atrial fibrillation, 67% of those presumed new. A total of 90 
(22%) of all participants with ischaemic stroke was less than 51 years of age. The mortality rate was 
statistically higher in patients who had AF. 
Conclusion   
The results from this study suggests that screening practices to detect both Atrial Fibrillation in 
asymptomatic patients, as well as in those with an ischaemic stroke, are not effective. With the 
increasing population life expectancy, and prevalence of cardiovascular disease, the prevalence of AF 
and its complications will increase. Since the risk of stroke related to AF can be reduced significantly 




Cerebrovascular disease remains one of the leading causes of morbidity and mortality globally. It affects 
15 million people annually and is responsible for 5 million deaths per annum, contributing to the 
growing burden of non-communicable diseases (NCDs) worldwide. (1,2) In South Africa, 
cerebrovascular disease was the fourth leading cause of death in 2016, responsible for 5.1 % of all 
deaths - the leading cause of death in individuals 65 years and older. (3) Globally approximately 3% of 
total health care system resources are dedicated to stroke, indicating that cerebrovascular accidents 
contribute to a significant economic burden on countries. (4,5) In 2008, Bertram et al., estimated that 
there are 75 000 strokes in South Africa each year, with 25 000 of these fatal within the first month. (6) 
The burden of disease due to stroke in 2008 in South Africa was 564 000 disability adjusted life years 
(DALYs), 17% thereof being contributed by years lived with disability (YLD). (6) 
Global estimates suggest that an estimated 80% of strokes are ischaemic, with 20% of all ischaemic 
strokes being cardio-embolic in nature. (7) Maredza et al., estimates that in the South African setting, 
71% are ischaemic, 21% haemorrhagic and the remainder are secondary to other causes, including  
vasculitis, HIV associated opportunistic infections, space-occupying lesions and trauma. (4,8) 
Embolisation of a mural thrombus in a patient with atrial fibrillation (AF) is the most common 
mechanism, and patients with AF have a fivefold increased risk for developing a stroke as well as a 
twofold increased risk of silent cerebral infarction. (7,9,10) Atrial fibrillation, the most common cardiac 
arrhythmia worldwide, has an estimated prevalence of 0,5-2% in the general population within western 
countries, (10,11) with a higher prevalence in males as compared to females. (9,11)  Current data, albeit 
sparse, indicates that the prevalence of AF in developing countries is slightly lower than that of the 
developed world. (11) Despite this lower prevalence of AF in developing countries, the number of AF 
related deaths increased by 196% from 1990 to 2013 in Sub-Saharan Africa (SSA), (12) as did the 
number of deaths from strokes, particularly ischaemic strokes with a 102% increase (12). In the United 
States, AF accounts for approximately 15% of all strokes, 36% of strokes for individuals aged >80, and 
up to 20% of cryptogenic strokes. This means that AF accounts for 100,000-125,000 embolic strokes 
per year, of which more than 20% are fatal. (13) 
The presence of AF in patients with newly diagnosed strokes is associated with prolonged 
hospitalisation, increased persistent disability, greater severity of disease, and elevated healthcare costs. 
(13–15) In addition to this, strokes that occur in the setting of AF have an increased risk of mortality 
compared to strokes of other aetiologies (30-day mortality OR, 1.84; 95% CI, 1.04 to 3.27). (9) Stroke 
severity and in-hospital mortality are also significantly greater in those with AF. (16,17) 
There is a paucity of data available reporting on the prevalence of AF in the urban population. With the 
increasing population life expectancy, and other cardiovascular disease, the prevalence of AF and its 
complications will likely increase. The aim of this study therefore is to determine the prevalence of 
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atrial fibrillation (AF) in patients with ischaemic stroke, as confirmed on CT scan, at a district level 
hospital in the Western Cape, South Africa. 
Methods 
Study design  
This is a descriptive study and data collection occurred retrospectively.  
Study setting  
This study was conducted at Mitchell’s Plain Hospital in Cape Town, South Africa. Mitchell’s Plain 
Hospital is a district hospital in the Mitchell’s Plain Health District of the Metro Region, which is 
approximately 32km from Cape Town’s city centre. The hospital serves a population of approximately 
750 000 - 800 000, which includes the population of Mitchell’s Plain and the greater part of Philippi, a 
large nearby township. The demographics of Mitchell’s Plain comprises of low- to middle-income 
families of which 90% are coloured, and Philippi which is a low-income community that comprises of 
90% black residents. 
Study population and sampling 
Inclusion criteria: All adult patients (age greater or equal to 18 years of age) who presented to 
Mitchell’s Plain Hospital EC with a clinical diagnosis of a stroke or cerebrovascular accident were 
eligible for inclusion. A diagnosis of stroke, for the purpose of this study was defined as patients with 
an ICD-10 code (primary or secondary) of a stroke: ICD-10 chapter: “Diseases of the circulatory 
system” and the ICD-10 subgroup of “cerebrovascular diseases”. Consecutive patients were included 
for the full study period from 1st April 2017 until 31st March 2018 (1 year). This date was chosen as it 
marks the commencement of data collection on the electronic patient register, HECTIS (Hospital and 
Emergency Centre tracking information system).  
Exclusion criteria: Ischaemic strokes secondary to causes other than thrombosis or an embolism were 
excluded, e.g. trauma, meningitis, and space occupying lesions (SOL). Patients diagnosed with transient 
ischaemic attacks were excluded, as well as patients with ischaemic stroke referred from other 
departments (internal medicine, surgery, psychiatric unit) – the incidence of these referrals are very low 
and would have complicated the data collection process. Patients transferred to other hospitals for 
admission where clinical data were inaccessible, were excluded from this study. Patients who were 
transferred for a CT scan to a different hospital were however included if the patient subsequently 
returned to Mitchell’s Plain Hospital for admission.  
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Data collection and management  
Data was collected in three phases: Phase 1 identified participants from the electronic patient register 
HECTIS. A search from within the database was conducted for keywords and ICD-10 codes with a 
clinical diagnosis of stroke. This included the parent ICD-10 group: “Diseases of the circulatory 
system” and the subgroup of “cerebrovascular diseases”. Demographic data was collated during this 
phase. Phase 2 involved scrutinizing the PACS (Picture archiving and communication system) database 
for CT Brain scans reports performed on patients identified from phase 1. The formal CT report, as 
reported by a qualified radiologist, was used for data collection. The absence of an intracranial bleed, 
or CT scan features indicative of an ischaemic event (embolic or thrombotic) was used to diagnose an 
ischaemic stroke. Phase 3 involved the collection of clinical data and demographic details for all patients 
identified from phase 2, by accessing the electronic database, Enterprise content management (ECM). 
All patients with a confirmed CT scan diagnosis of an ischaemic stroke were included in this phase. 
Clinical notes were scrutinised for ECGs and each ECG was independently assessed by the two 
Emergency Physicians for the presence of AF. Clinical notes, as well as previous ECGs, of patients 
were assessed to help decide whether the AF is presumed new or existing. In those with existing AF, 
the anticoagulation plan was documented. Random case files (5%) were cross-checked by the study 
investigators to ensure that data collection was accurate. 
Ethical considerations 
Existing data was collected retrospectively, and data was deidentified after the data collection process 
was completed. Folder numbers were used to track the data collection process through the different 
phases. This study received ethical clearance from the University of Cape Town Human Research 
Ethics Committee (HREC: 790/2018) 
Data Analysis 
This study was powered to analyse the primary outcome variable, prevalence, A sample size calculation 
suggested a minimum of 196 samples, with precision of 5%, an expected prevalence of 15% and a 
population size of 800 000. Categorical data was described as proportions/percentages and descriptive 
statistics. Numerical data was described by median and interquartile range (IQR). A 95% confidence 
interval (CI) is provided when applicable and statistical significance is defined as a p<0.05. Categorical 




During the study period of 12 months, 45 944 patients visited the emergency centre of which 36 028 
(78%) were adults. The proportion of adult patients with a diagnosis of stroke was 2%. Of those, 11% 
met exclusion criteria and 6.5% had stroke mimics. Of the 598 that was included, 22% did not have CT 
scans. Of the CT confirmed strokes, 88% were ischaemic and 10% of those did not have and ECG 
performed during the clinical stay. Figure 1 depicts a flow diagram of study participants. 
Total patients with stroke 
diagnosis 
n=725 
Total patients meeting 
exclusion criteria 
n=80 
Total patients with stroke 
mimics 
n=47 
Total patients with stroke 
without CT scan 
n=130 







No ECG performed 
n=39 
Presumed New  
Atrial Fibrillation 
n=26 






Total patients with CT 
confirmed ischaemic 
stroke and ECG 
n=373 
Figure 1: Flow diagram of study participants 




11% of all participants with CT confirmed ischaemic strokes had atrial fibrillation, 67% of those 
presumed new. Of the 13 participants with existing atrial fibrillation, none were therapeutically 
anticoagulated (Figure 2). 
The presence of atrial fibrillation was confirmed by two emergency physicians, who individually 
evaluated all ECGs (n=373). Initial agreement was achieved in 98.66% of observations with a Cohen’s 
Kappa of 0.931 (95% CI 0.871 to 0.991). The five ECG’s that were not agreed upon were discussed 














Figure 3 illustrates a scatter plot of the age distribution of participants (n=412) with ischaemic stroke. 
The graph depicts a normal distribution around a median of 61. The interquartile range is 16 years and 
50% of all strokes occurred between 52 and 68 years of age. The youngest participant was 27 years old 

















Figure 2: Breakdown of anticoagulation therapy for patients with existing AF 
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Figure 3: Scatter plot of age distribution of participants with ischaemic stroke 
The proportion of patients with ischaemic stroke who has atrial fibrillation (n=39) increased 
significantly from 70 years onwards, as illustrated in Figure 4. 
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Proportion of patients with ischaemic stroke who has
atrial fibrillation per age category (n=39)
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Table 1 compares the demographic details of all participants who met inclusion criteria. The p-values 
were calculated by comparing only participants with ischaemic and haemorrhagic strokes. 











Male 209 (51%) 34 (61%) 19 (40%) 72 (55%) 
0.199 
Female 203 (49%) 22 (39%) 28 (60%) 58 (45%) 
Age 
£50 years old 90 (22%) 17 (30%) 16 (34%) 18 (14%) 
0.175 
>50 years old 322 (78%) 39 (70%) 31 (66%) 112 (86%) 
Comorbidities 
Hypertension 320 (77%) 33 (59%) 0.004 
Diabetes 159 (36%) 6 (11%) <0.001 
Smoking 118 (29%) 12 (21%) 0.340 
HIV positive 39 (9,5%) 5 (9%) 1 
Dyslipidaemia 89 (22%) 3 (5,3%) 0.002 
Excessive alcohol use 18 (4%) 0 0.148 
Valve replacement 7 (1,7%) 1 (1,8%) 1 
CT-scan 
In-patient 364 (88%) 56 (100%) 44 (94%) 
0.004 
Out-patient 48 (12%) 0 3 (6%) 
EC Disposition 
Admitted / Transferred 337 (82%) 49 (88%) 37 (79%) 66 (51%) 
0.028 
Discharged 74 (18%) 3 (5%) 10 (21%) 57 (44%) 
 EC Died 1 (0,2%) 4 (7%) 0 7 (5%) 
Outcome 
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Survived to discharge / 
transfer 
375 (91%) 52 (93%) 47 (100%) 
 0.080 
In-patient death 37 (9%) 4 (7%) 0 
 
The proportion of males and females, as well as young age (£45 years old), was not statistically different 
between the two groups. With regards to risk factors, hypertension, diabetes and dyslipidaemia were 
statistically more prevalent in those who had an ischaemic stroke. Smoking, retroviral status, excessive 
ethanol use, and prior valve replacement were not statistically different between the two groups. All 
participants with intracranial bleeds received in-patient CT-scans, in comparison to those with 
ischaemic strokes where 12% were performed as an out-patients – the difference between the two 
groups being statistically different. 22% of all participants with ischaemic strokes were discharged from 
the EC, significantly higher than in the haemorrhagic group. The proportion of patients who survived 
to hospital discharge was not significantly different.  
 
Table 2 compares the demographic details of participants with ischemic stroke between those who had 
atrial fibrillation and those who did not. The p-values were calculated by comparing only participants 
with atrial fibrillation and those without atrial fibrillation. 
 












Male 18 (46%) 171 (51%) 20 (51%) 
0.613 
Female 21(54%) 163 (49%) 19 (49%) 
Age  
£50 years old  4 (10%) 76 (23%) 10 (26%) 
0.097 
>50 years old 35 (90%) 258 (77%) 29 (74%) 
Comorbidities  
Hypertension 35 (90%) 260 (78%) 25 (64%) 0.971 
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Diabetes 12 (30%) 136 (40%) 11 (28%) 0.299 
Smoking 6 (15%) 104 (31%) 8 (20%) 0.042 
HIV positive 1 (3%) 35 (10%) 3 (8%) 0.153 
Dyslipidaemia 5 (13%) 81 (24%) 3 (8%) 0.158 
Excessive alcohol use 1 (3%) 15 (4%) 2 (5%) 1 
Valve replacement 4 (10%) 3 (0,8%) 0 0.003 
CT-scan  
In-patient 36 (92%) 292 (87%) 36 (92%) 
0.602 
Out-patient 3 (8%) 42 (13%) 3 (8%) 
EC Disposition  
Admitted 36 (92%) 268 (80%) 33 (85%) 
0.081 
Discharged 3 (8%) 65 (19%) 6 (15%) 
Died 0 1 (0,3%) 0  
Outcome  
Survived to discharge 29 (74%) 310 (92%) 36 (92%) 
0.001 
In-patient death 10 (26%) 24 (7%) 3 (8%) 
 
There was no statistically significant difference between the proportion of males and females, as well 
as young age, between those with atrial fibrillation and those without. Smoking was statistically more 
prevalent in those without atrial fibrillation, while a prior valve replacement was statistically more 
prevalent in those participants with atrial fibrillation. The other risk factors have a similar distribution 
in the two groups. Both EC disposition and the proportion of participants receiving in-patients CT scans, 
were not significantly different in the two groups. The proportion of patients who died was statistically 
higher in patients who had AF. 
Discussions 
The proportion of CT confirmed ischaemic strokes of 88% is higher than international figures where it 
accounts for 80% of all CVAs. (7,14) Limited data from South African suggests that the number should 
be closer to 71%. (4) This difference could however be explained by the fact that 20% of patients with 
a clinical diagnosis of an ischaemic stroke did not receive a CT scan – not an uncommon practice in 
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resource challenged settings. Chunga et al reports that with regards to emergency access to imaging of 
the brain, 81% of LMICs had access to CT scans, with 84% of them having 24-hour access to radiology 
services, compared to HICs with 83% and 98% respectively. (18) Global data on the availability of 
medical devices in 2014 estimated that the number of CT scan machines per 1 million population as 
only 0.32 in low-income centres compared with 42 in high-income countries, and neuro-diagnostic tests 
are often inaccessible or unaffordable to many patients in low-income settings. (19) 
HIV, a known risk factor for ischaemic strokes, was present in approximately 10% of cases, close to 
double seen in HICs, where the incidence of HIV positive patients developing strokes are between 1-
5%, although a higher proportion (4–34%) have cerebral ischaemic areas at autopsy. (20) Ischaemic 
stroke seems to be more frequent than cerebral haemorrhage in patients with HIV, at least in a hospital-
based series from sub-Saharan Africa, where it is reported in over 90% of HIV-associated strokes. (20–
22) Interestingly enough this is not depicted in this population where an equal percentage was seen in 
both ischaemic and non-ischaemic CVAs. 
The prevalence of AF in patients with ischaemic strokes is 11%, lower than the 15-20% reported by the 
United States, (13,16) and significantly lower than other HICs, where it is reported as being close to 
30%. (23,24) A possible explanation for the lower than expected prevalence in AF, is that our study 
only assessed ECGs of patients with confirmed ischaemic CVAs on CT scan – excluding those who did 
not have radiological confirmation (20%). In addition, the majority of patients with no AF only had one 
ECG, which was done on admission. None had continuous/Holter testing and very few had repeat ECGs 
during their stay in hospital, thus reducing the probability of detecting intermittent/paroxysmal AF. It 
should be noted that continuous ECG monitoring for periods of 24 hours or more (secondary screening) 
in stable patients can approximately double the number of AF cases diagnosed when compared to a 
single short ECG recording. (25)  
Two thirds of those with AF were newly diagnosed on presentation which is often the case, suggesting 
that primary screening practices are lacking. (16) AF satisfies most of the WHO’s criteria for a disease 
suitable for screening. (26) Current European Society of Cardiology guidelines recommend 
opportunistic screening for AF by pulse taking or ECG rhythm strip instead of a systematic approach 
in people more than 65 years of age. (26,27) This single timepoint opportunistic pulse palpation with 
confirmatory ECG in elderly adults is potentially feasible and beneficial for primary stroke prevention. 
(28) In a Canadian study by Tarride et al, screening for AF, in seniors greater than 65 years of age 
during routine appointments with their family physicians, with single lead-ECG is a highly cost 
effective strategy with an incremental cost per quality-adjusted life-year (QALY) gained of 
CAD$4788. (29) which equates to R51 200. Although the risk of stroke related to AF can be reduced 
by 64–70% by oral anticoagulation, underutilisation of this effective treatment and delayed diagnosis 
remain major obstacles, (26,30) thus screening at primary care level is of utmost importance.  
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Despite increasing data on community-based AF screening becoming available in recent years, 
questions remain regarding the most appropriate setting and tools. Large-scale systematic AF screening 
in the community (>4,000 individuals) have been conducted in different countries and regions with AF 
detection (new diagnosis of AF) rates ranging from 0.5-5.6 %. (26) However, as revealed in a Hong 
Kong based screening program, the AFinder programme, utilising interpretable smartphone ECGs to 
screen for AF, the effectiveness was significantly weakened by the lack of a management pathway, and 
the number needed to screen (NNS) for one patient receiving appropriate oral anticoagulation for newly 
diagnosed AF was 671. (26) This was in comparison with a Swedish based screening program, the 
STROKESTOP study where the NNS was 209 because of a structured follow up. (26,31) Therefore a 
structured downstream management pathway should be a necessary component of any community AF 
screening programme. (26) 
In many HICs mass AF screening of the general population at primary care has become more feasible 
with the availability of new tools, especially those capable of producing single-lead smartphone ECGs. 
(26,32) However the sensitivity and positive predictive value of these automated diagnostic algorithms 
of any ECG-producing tool has to be high enough to save the intermediate step of interpretation by a 
doctor. (26) 
There were no statically significant gender distribution difference, whereas internationally AF is seen 
more commonly in males, and male gender being an independent risk factor of AF. (9,11) This could 
be due to a small sample size, as this study was only powered to detect prevalence. Advancing age is a 
significant risk factor for the development of AF, and with the increase in life expectancy in HIC the 
prevalence of AF will be higher compared to this population where the median age of ischaemic strokes 
were 61 years.  
The median age of CVAs in this population was 61 years, half of all the CVAs occurred between 52 
and 68 years, and most alarmingly, 22% of all the ischaemic strokes occurred in individuals under the 
age of 51 years. This alarming number is significantly higher compared to HIC, with a prevalence of 
18,1/100 000 in a French population, obtained from the French Stroke Registry, 10,8/100 000 in a 
Finnish based study and 12,1/100 000 in young Italians. (33,34) A systematic review on the incidence 
of stroke in young adults was published by Marini et al who analysed 29 studies including 3,589 patients 
under 45 years of age with first-ever stroke, published between 1980 and 2009. Crude rates ranged from 
5.76/100 000 to 39.79/100 000 and standardized rates ranged from 6.14/100 000 to 48.51/100 000. (35) 
According to Bejot et al, the incidence of young strokes, i.e., patients less than 55 years has increased 
by 40% between 1994-2012, coupled with an increase in hospitalisation, predominately by the increased 
rates of ischaemic stokes, as seen in the Mitchell’s Plain population. (34) Possible reasons could reflect 
changes in the burden of vascular risk factors. A rise in the prevalence of type 2 diabetes mellitus, 
hypercholesterolemia, hypertension and obesity that has been observed in high-income countries, as 
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well as LMIC. In addition, cigarette smoking and alcohol abuse are frequent in young people and have 
tended to increase over time. These classic risk factors coupled by a high rate of rheumatic fever and 
rheumatic heart disease resulting in valvular heart disease and AF, is an additional risk factor for the 
development of an ischaemic stroke, with valvular heart disease being statically significant for the 
development of AF in this population. In addition to all the above HIV could also be a significant risk 
factor for young CVAs, and further research is required to determine the link between the two 
particularly in this and other similar settings. Preventive measures are of paramount importance in this 
young population as it is well documented that the societal impact is high due to the greater number of 
years of life lost and the resulting loss in productivity. (36) 
Anticoagulation is complex, as there are several indications, agents and dosing regimens to choose 
from. (37) In the South African public healthcare sector, these difficulties are exacerbated by our diverse 
patient populations, some of whom have multiple comorbidities, and limited access to the various 
anticoagulants which are available. (37) A fairly recent South African study by Ntlokotsi et al 
essentially looked at patients with valve replacements, with or without AF, over a 3-year period with 
the optimum INR target ranges for all participants estimated to be between 2.0– 3.5. (37,38) Alarming 
though the quality of warfarin anticoagulation of the participants with valve replacement was found to 
be inadequate as indicated by percentage time in treatment range (TTR) which was 49.7% for all study 
participants compared with the ideal TTR of 70% and above. (38) Similar results were demonstrated 
by Sonuga et al, looking at anticoagulation outcomes of patients on warfarin therapy in an urban hospital 
in Cape Town, South Africa. (39) Possible explanations for warfarin’s TTR in this study include non-
compliance, drug-drug interaction, drug- food interactions and patient comorbidities. (37,40) All these 
complexities are found in our population.  
The most significant limitation of this study is that it may not represent the true prevalence of AF in 
patients with ischaemic CVAs due to the following factors: (i) sampling excluded patients who 
presented to primary health care facilities and/or those who were discharged from these facilities; (ii) 
sampling excluded patients who died before reaching the hospital; (iii) sampling did not include all 
patients who are referred to tertiary facilities; (iv) patients who have paroxysmal AF may have been 
missed by routine screening practices and (vi) the data collection process was retrospective and 
dependant on clinical notes and accurate record keeping, and lastly (vii) the prevalence of AF in 
ischaemic CVA may be somewhat misleading as 10% of the ischaemic CVA patients did not have an 
ECG. Selection bias may further influence the results because of the fact that only 80% of included 
patients had a CT scan. This may have skewed the data towards the null value, considering that patients 
with embolic/ischaemic strokes often present much more benign than those with intracranial 
haemorrhage. This could have led to an underestimation of the prevalence of AF in ischaemic CVA’s. 
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Anticoagulation and screening practices may not represent the greater Western Cape community and 
may reflect district or institution specific practices.   
Future research should attempt to calculate the true prevalence of atrial fibrillation in patients with 
ischaemic strokes, practically involving a multicentre data collection model across different levels of 
care. A standardised protocol and clerking sheet will also provide more information and provide 
cognitive checks to perform minimum investigations. The reasons and barriers for the limited primary 
and secondary screening for atrial fibrillation should be sought and addressed.  
Conclusions 
Atrial fibrillation is a major risk factor for developing ischaemic cerebrovascular accidents. With the 
increasing population life expectancy, and other cardiovascular disease, the prevalence of AF and its 
complications will increase. Although the risk of stroke related to AF can be reduced significantly by 
oral anticoagulation, delayed diagnosis and ineffective screening practices remain major obstacles. This 
study confirms that a significant proportion of patients with an ischaemic stroke have undiagnosed AF 
and that secondary screening of those with an ischaemic stroke is challenging. It is paramount that all 
patients that present with CVAs receive at least an ECG on admission and perhaps prior to discharge. 
Since atrial fibrillation is a modifiable risk factor, further studies should aim to explore barriers and 
challenges to effective screening. Another important discovery from this study is that there is a high 
proportion of patients with “young CVAs”. This was not the main focus of this study but definitely 
needs to be investigated and more research is needed to identify why this is so and why the prevalence 
of young CVAs are increasing. 
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Stroke remains one of the leading causes of morbidity and mortality worldwide, affecting both high- 
and low- to middle-income countries alike, resulting in an immeasurable human, economic and societal 
burden. In South Africa, cerebrovascular disease was the fourth leading cause of death in 2016, 
responsible for 5.1 % of deaths, and the leading cause of death in individuals 65 years and older. In 
high-income countries, AF accounts for approximately 15% of all strokes, but there is however a 
paucity of data available on the prevalence of atrial fibrillation in stroke in South Africa. This study sets 
out to determine the prevalence of atrial fibrillation in patients with strokes, as confirmed on CT scan, 
in a district level hospital in the Western Cape, South Africa. 
 
Methodology 
This descriptive study will be conducted at Mitchells Plain Hospital in Cape Town and data will be 
collected for a year. Patients diagnosed with a stroke will be identified from the electronic patient 
register and relevant radiology and clinical data will be sourced from the various electronic databases. 
CT scan reports will determine the diagnosis of an ischaemic stroke and ECG’s will be independently 
screened for atrial fibrillation by two emergency physicians. A 95% confidence interval (CI) will be 
provided and statistical significance will be defined as a p<0.05. 
 
Ethical Considerations 
The research project will de-identify the data in the very beginning of the data collection period and 
therefore poses minimal risk to the participants. Data will also be aggregated, and no individual data 
will be published and reported on. By including the clinical data of participants, it will in no way affect 
the rights and welfare of participants. A waiver of written consent will therefore be applied for. Ethical 
approval will be obtained from the Human Research Ethics Committee of the University of Cape 
Town. Thereafter, institutional approval will be obtained from Mitchell’s Plain Hospital.  
 
Conclusions 
This is one of the first studies of its kind in the Western Cape and a reasonably big study with regards 
to number of participants and power of measurements. The study will provide insight into the 
prevalence of atrial fibrillation in patients with strokes in an urban setting. Information from this study 
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should be used to adopt screening tools for atrial fibrillation, early risk stratification assessments and 





Stroke, also known as cerebrovascular accident (CVA), is defined as a neurologic deficit caused by a 
cerebrovascular problem which persist for more than 24 hours or causes death within 24 hours. (1) It is 
characterised by focal or global cerebral functional impairment, affecting both motor and sensory 
function, and rapidly evolving. (1)  
Cerebrovascular disease remains one of the top causes of morbidity and mortality worldwide, both in 
high-income countries (HICs) and low- and middle-income countries (LMICs). (2) In South Africa 
cerebrovascular disease was the fourth leading cause of death in 2016, responsible for 5.1 % of deaths 
(3) , and the leading cause of death in individuals 65 years and older. (3) Globally approximately 3%
of total health care system resources are dedicated to stroke indicating that cerebrovascular accidents
composes a significant economic burden on countries. (4,5) There is a paucity of local data that
describes the financial impact that stroke care and resources utilised, amount to.  Maredza et al., it is
stated that the “total direct costs of strokes were estimated to be 2.5-4.2 million in the year 2012 in a
small rural community in South Africa”. (4).  This analysis is based on a population of approximately
90,000 people residing in the Agincourt sub-district of Mpumalanga province, north-east of South
Africa. (4)
In 2008, Bertram et al., estimated that there are 75 000 strokes in South Africa each year, with 25 000 
of these fatal within the first month. (6)  The burden of disease due to stroke in 2008 in South Africa 
was 564 000 Disability adjusted life years (DALYs). Of this, 17% is contributed by Years lived with 
disability (YLD). (6)  
In 2008 in the United States the total direct and indirect costs of stroke was estimated to cost the 
economy an estimated 65.5 Billion dollars, where the indirect costs incurred were due to loss of 
productivity resulting from morbidity and mortality. (5) In addition to this, informal care, which is often 
overlooked, remains of utmost importance to maintain stroke survivors in the community resulting in 
an additional economic and social burden. (5)  
Fifteen percent of stroke survivors require long-term institutional care, while 70% are left with 
significant physical, emotional or cognitive impairment, such as depression, anxiety, communication 
difficulties, gainful enjoyment and dementia. (7)  The need of support for common daily activities and 
social integration directly impacts quality of life of patients and their relatives, who frequently take on 
the role of caregivers. (5,7)  
An estimated 80% of strokes globally are ischaemic in nature, and the rest non-ischaemic, either being 
haemorrhagic or secondary to a different cause. (2)  Maredza et al., estimates that in the South African 
setting 71% are ischaemic, 21% being haemorrhagic  and the remainder secondary to a different cause. 
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(4) International data states that one fourth of all ischaemic strokes are cardio-embolic in nature. (1,2)
Embolization of a mural thrombus in a patient with atrial fibrillation (AF) is the most common
mechanism, and patients with AF have a fivefold increased risk for developing a stroke. (2,8,9)  In
addition to this, the presence of AF in patients with newly diagnosed strokes is associated with
prolonged hospitalisation, increased persistent disability and elevated healthcare costs. (1,10,11)
Atrial fibrillation (AF), the most common cardiac arrhythmia worldwide, has an estimated prevalence 
of 0,5-2% in the general population within western countries (9,12), with a higher prevalence in males 
compared to females. (8,12)  Current data, albeit sparse, indicate that the prevalence of AF in developing 
countries are slightly lower to that of developed world. (12) Despite this lower prevalence of AF in 
developing countries  the number of AF related deaths increased 196% from 1990 to 2013 in Sub-
Saharan Africa (SSA) (13), as did the number of deaths from strokes, particularly ischaemic strokes 
with a 102% increase. (13) As AF becomes more prevalent with age, the incidence of AF is estimated 
to increase progressively in the future with the increased mortality and morbidity associated with it. 
(12) 
In the United States AF accounts for approximately 15% of all strokes, 36% of strokes for individuals 
aged >80, and up to 20% of cryptogenic strokes. (11) This means that AF accounts for 100,000-125,000 
embolic strokes per year, of which more than 20% are fatal. (11) 
Data on the general prevalence and incidence of AF in Africa are sparse, particularly in South Africa 
with small studies estimating it to be 5.6 cases per 100000 per year (14), with nil data available about 
the prevalence of AF in patients with ischaemic strokes in an urban environment.  
Motivation 
Atrial fibrillation is a major risk factor for developing ischaemic cerebrovascular accidents, as well as 
other cardio-embolic complication, particularly in our urban environments. There is a paucity of data 
available reporting on the prevalence of AF in the urban population, particularly in patients with CVAs. 
With the increasing population life expectancy, and other cardiovascular disease, such as hypertension, 
diabetes, congestive cardiac failure and valvular heart disease the prevalence of AF is sure to increase, 
as well as its complications.  
This study will help to provide much needed information about the prevalence of AF in this particular 
population, as well as other demographics of CVAs. The results of which can be used to adjust hospital 
protocols, hospital and community screening of AF, early risk stratification and early initiation of 
anticoagulants to prevent the cardio-embolic complications of AF, particular CVAs. With an overall 
reduction in patient mortality and morbidity and a decrease in economic burden associated with CVAs 
and other AF related complications. 
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Aims 
To determine the prevalence of atrial fibrillation (AF) in patients with ischaemic cerebrovascular 
accidents, as confirmed on CT scan, in a district level hospital in the Western Cape, South Africa. 
Objectives 
1. To calculate the proportion of patients presenting to the EC with a suspected stroke.
2. To stratify all clinically suspected strokes into CT diagnosis (haemorrhagic vs ischaemic vs
other) and to describe the demographics for each category.
3. To determine the prevalence of atrial fibrillation in patients with confirmed ischaemic stroke
and to establish whether it is presumed new or existing.
4. To describe the anticoagulation treatment plan of patients with existing AF.
5. To calculate the proportion of patients on Warfarin that are therapeutic or sub-therapeutic.
Methodology
Study design  
This is a descriptive study collecting data as a retrospective chart review. 
Study setting  
This study will be conducted at Mitchells Plain Hospital in Cape Town, South Africa. Mitchell’s Plain 
Hospital is a district hospital in the Mitchell’s Plain Health District of the Metro Region, which is 
approximately 32km from Cape Town’s city centre. The hospital serves a population of approximately 
750 000 - 800 000, which includes the population of Mitchells Plain and the greater part of Philippi, a 
large nearby township. The demographics of Mitchells Plain comprises of low- to middle-income 
families of which 90% are coloured, and Philippi which is a low-income community that comprises of 
90% black residents. 
Study population and sampling 
Inclusion criteria  
1. Adult patients (age greater or equal to 18 years of age) who presented to Mitchell’s Plain
Hospital EC with a clinical diagnosis of a stroke or cerebrovascular accident. A diagnosis of
stroke for the purpose of this study is defined as patients with an ICD-10 code (primary or
secondary) of a stroke: ICD-10 chapter: “Diseases of the circulatory system” and the ICD-10
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subgroup of “cerebrovascular diseases”. All patients that meet the above-mentioned criteria 
will potentially be eligible for inclusion. 
2. Serial/consecutive patients will be included for the full study period.
3. The data collection period is for 1 year and from 1st April 2017 until 31st March 2018. This date
was chosen as it marks the commencement of data collection on the electronic patient register,
HECTIS (Hospital and Emergency Centre tracking information system)
Exclusion criteria 
1. Patients transferred to other hospitals for admission, where clinical notes would be inaccessible
will be excluded from this study – patients who are referred for a CT scan at a different hospital
(GSH) will be included if the patient subsequently returns to Mitchell’s Plain Hospital for
admission.
2. Ischaemic strokes secondary to causes other than thrombosis or an embolism will be
excluded, e.g. in trauma, meningitis, etc.
3. Patients diagnosed with transient ischaemic attacks.
4. Patients with CVAs referred from other departments (internal medicine, surgery, psychiatric
unit) – the incidence of these referrals is very low and would complicate the data collection
process.
Data collection and management  
Data will be collected in three consecutive phases: 
Phase 1: 
Participants will be identified from the electronic patient register HECTIS. A search from within the 
database will be conducted for keywords and ICD-10 codes with a clinical diagnosis of stroke. This 
will include the parent ICD-10 group: “Diseases of the circulatory system” and the subgroup of 
“cerebrovascular diseases”. All patients that meet the above-mentioned criteria will potentially be 
eligible for inclusion. Demographic data will be collected from HECTIS and the folder numbers will 
be the only identifying variable that will be included at this stage. It will be necessary to link the first, 
second and third stages of the data collection period.  
Phase 2: 
The PACS (Picture archiving and communication system) database will then be scrutinised for CT 
Brain scans performed on patients identified from phase 1. The formal CT report, as diagnosed by a 
qualified radiologist, will be used for data collection. The absence of an intracranial bleed, or CT scan 
features indicative of an ischaemic event (embolic or thrombotic) will be used to diagnose an ischaemic 
58 
stroke. It is expected that a few patients may have received CT scans at a referral hospital (Groote 
Schuur (GSH) as Mitchells Plain Hospital does not have after hour CT scan services). Groote Schuur 
Hospital’s PACS system will then be searched for CT scan reports.  
Phase 3: 
The electronic database, ECM, will be scrutinised for all patients identified from phase 2 of the data 
collection process. All patient with a confirmed CT scan diagnosis (or strong suspicion) of an ischaemic 
stroke will be included in this phase. Demographic details and comorbid conditions will be collected 
but no personal identifying information will be included. At this stage of the study, all data will be de-
identified by linking it with a study number. 
Patients clinical notes will be searched for ECG’s. All ECG’s will be assessed independently by the 
two project supervisors who are emergency physicians for the presence of AF. All ECG assessments 
that differed between the two emergency physicians will be discussed to reach consensus. A third expert 
(cardiologist) will be consulted if consensus cannot be reached. Clinical notes, as well as previous 
ECGs, of patients will be assessed for whether the AF is presumed new or existing. In those with 
existing AF, the anticoagulation plan will be assessed, as well as whether the participant is on Warfarin 
(therapeutic or not), Aspirin or on no anticoagulation. A graphical representation of the data-collection 
process can be found below: 
Missing data or incomplete records: 
Cases will be excluded if patients’ clinical data or information is missing or inaccessible. The number 
of missing cases will be clearly described and as well as much as possible of the relevant descriptive 
details (demographics, etc.). This will allow for comparison between cases and missing data. The 
investigators will make every effort to prevent missing data, including meeting with ECM of PACS 
administrators to try and minimise missing / lost data. A flow chart of cases and missing data/incomplete 
records will be presented. 
Because this will be a descriptive study and because it will not be testing a hypothesis, incomplete data 
will be included and described up to the point where it can no longer be analysed. This will clearly be 
documented and described. Demographics will be presented for both missing and incomplete data so 
that it can be compared to those with complete data. The expected effect is described in the limitations 
section. 
In those cases where the analysis of clinical data provides uncertain information, it will be presented as 
“unsure” and not categorised into a definitive category, for example if unsure whether AF is presumed 
new or existing.  
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Variables and data sources: 
Phase 1 
Source: HECTIS 
Variables: Folder number; Gender; Age; ICD-10 diagnosis; date of admission 
Phase 2 
Source: PACS 
Variables: CT performed - yes or no; date of CT scan; diagnosis (3 categories) 
Phase 3 
Source: ECM 
Variables: comorbid diseases; ECG present or not; ECG diagnosis AF or not (Specialist 1); ECG 
diagnosis AF or not (Specialist 2); AF presumed new or existing; Anticoagulation plan or no treatment 
plan; Warfarin or not; Aspirin or not; INR level (if on Warfarin);  
60 
Figure 5: Proposed structure of data collection 
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Data safety and monitoring 
Care will be taken to protect the identity of each patient. No identifying data will be collected. 
Initially the patients folder number will be obtained from the PACS database (which will be 
necessary to tract the patients ECM records), thereafter the demographics and clinical data 
will be collected. The data will be de-identified from this step onwards. A study number will 
be given to each patient and thereafter only study numbers will be used. Names and folder 
numbers will be saved against study numbers in a separate file in cases of a query. Only study 
personnel will have access to the files and it will be password protected and saved in a 
university computor at UCT, which will also be password protected. Also, information 
obtained will be backed up in a cloud server which will also be password protected and 
accessed only by study investigators. 
Data Analysis 
For this study to be powered to measure prevalence, a minimum of 246 samples are required, 
if we accept a precision of 5%, an expected prevalence of 20% and a population size of 
600 000. An informal audit revealed an estimate of 60 undifferentiated strokes per calendar 
month presents to Mitchell’s Plain Emergency Centre. Considering the fact that not all strokes 
are ischaemic, data over a one-year period will provide a sufficient sample size to mitigate for 
this. Categorical data will be described in percentages and descriptive statistics. Continuous 
variables will be described by mean +/- standard deviation (SD) or median and interquartile 
range (IQR). A 95% confidence interval (CI) will be provided and statistical significance will 
be defined as a p<0.05. Categorical data will be compared using the Fisher’s exact test or Chi-
squared test, depending on the sample size. Continuous variables will be compared with the t-
test or Mann-Whitney test as appropriate. 
Ethical considerations 
Risk to patients  
Routine clinical data will be collected retrospectively from folders and the electronic database, 
ECM. Extracting data from an existing database essentially renders it a large-scale clinical 
folder audit and patient care will thus not be affected in any way. The research project will de-
identify the data in the very beginning of the data collection period and therefore poses 
minimal risk to the participants. Data will also be aggregated, and no individual data will be 
published and reported on. By including the clinical data of participants, it will in no way 
affect the rights and welfare of participants. A waiver of written consent will therefore be 
applied for. 
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In the event of a missed clinical diagnosis that has become evident during the data collection 
period, the relevant clinician or clinical team will be informed as soon as possible, for example 
undiagnosed atrial fibrillation. 
Risk to community 
This project will only benefit the community of Mitchell’s Plain. It may become the basis of 
future research to improve the plight of the at-risk population with regards to minimising 
stroke prevalence in AF. This study poses no risk to the community. 
Risk to clinician  
No data specific to any clinician will be collected.  
Risk to institution 
This study poses no risk to Mitchell’s Plain Hospital. 
Ethical approval will be obtained from the Human Research Ethics Committee of the 
University of Cape Town. Thereafter, institutional approval will be obtained from Mitchell’s 
Plain Hospital.  
There will be no reimbursement for participation. 
Limitations and strengths 
Strengths 
This is one of the first studies of its kind in the Western Cape and a reasonably big study with 
regards to number of participants and power of measurements. The information gained from 
this study could form the basis for future studies to help decrease the prevalence of embolic 
stroke in patients with AF. 
Limitations 
The study may not represent the true prevalence of AF in patients CVAs due to the fact: 
1. Sampling does not include patients who present to community health centres or
general practitioners and/or those who were discharged from these facilities and
subsequently not referred to district hospitals
2. Sampling does not include patients who died before reaching the hospital
3. Sampling does not include those patients who are referred to tertiary facilities
4. It may be difficult to distinguish between embolic and thrombotic CVAs on CT scans
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5. Those patients who have paroxysmal AF may be missed by our screening, yet the risk
of embolic CVAs and other cardio-embolic events are the same as those with chronic
AF.
6. Patients with existing AF will be defined as a clinical documentation of the presence
of AF in historic notes, whether in the clinical notes, discharge summaries or whether
it was documented as ICD-10 code on previous episodes.
Selection bias my influence results if not all patients receive CT scans of the brain. This may 
lead to skewed data, considering that patients with embolic/ischaemic strokes often presents 
much more benign clinically than those with intracranial bleeds. Many patients with 
ischaemic/embolic strokes may therefore not have had a CT scan, and this may skew the effect 
towards the null value. A larger sample my therefore be necessary in an attempt to mitigate 
this potential source of bias. 
Anticoagulation and screening practices may not represent the greater Western Cape 
community and may reflect district or institution specific practices.  
It is fair to expect missing or incomplete data, due to the fact that this is a retrospective study. 
Even though the investigator will clearly describe and present the demographics of the missing 
/ incomplete data, it may affect the outcome and conclusion if the number of missing data if 
significant (>5%). This potentially will result in a smaller sample size and therefore decrease 
the power of the study, introducing a selection bias. The investigator will try to prevent 
missing or incomplete data as far as possible. Missing or incomplete data will be presented in 
as much as possible detail, to allow for comparison with cases.  
Data dissemination plan 
Publication in a peer review journal is expected. 
The study will provide insight to the prevalence of AF in those patients with cerebrovascular 
disease in an urban hospital within Cape Town. Further studies could build from it, ultimately 
to establish early screening tools for AF, early risk stratification and the appropriate use of 
anticoagulation to prevent cardioembolic ischaemic strokes as well as other AF associated 
cardioembolic events. The results obtained from this study will be presented to the hospital 
and other hospitals in the substructure so that they can plan and improve services. This could 
result in protocol change and could suggest a need for training and upskilling of clinicians, 
e.g. if a very high proportion of AF is undiagnosed, screening programs should be improved.
And if those with AF have subtherapeutic anticoagulation therapies, it could suggest improved
monitoring at a primary health care level.
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Project Time Line  
Table 3: Project timeline 
2018 Jan Feb Mar Apr May Jun July Aug Sep Oct Nov Dec 
EMDRC     X  X       
Ethics      X X      
Hospital 
Permission 
       X X    
Data 
Collection 
         X X  
Data 
Analysis 
           X 
2019 Jan Feb Mar Apr May Jun July Aug Sep Oct Nov Dec 
Writeup X X X          
Submission    X X        
 
Resources and budget  
Hardware: Laptop, Hard drive- available, nil cost  
Software: Word processing software, referencing software, data management software and 
statistcal analysis software- available, nil cost 
The total budget of R1300 will be carried by the research team.  
 
Table 4: Budget 
May 2018 – July 2019 
Item Description  Unit cost No of 
Units 
Total cost 
Consumables     
1. materials and supplies 
    
2. materials and supplies 
    
3. specialised services 
    
4. office supplies, printing & 
reproduction for data collection Stationary-pens, notepads, files   R500 
5. office supplies, printing & 
reproduction for reports Printing-data collection, reports, paper   R300 
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Research travel 
1. travel to sites




Travel to UCT library: 5 trips= 5km x 10= 50km R100 
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